Response to " NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.
Lilach AizenbudDavid A SchoenfeldJasmine I CaulfieldJacqueline E MannMatthew R AustinAna Luisa PerdigotoKevan C HeroldHarriet M KlugerPublished in: Journal for immunotherapy of cancer (2023)